The year 2026 represents a "Great Rationalisation" for the European HealthTech and MedTech sector. The era of easy money, regulatory ambiguity, and "growth at all costs" is over. It has been replaced by a landscape defined by industrial rigor, regulatory enforcement, and financial discipline. For founders, the path to maximising shareholder value lies not in chasing hype cycles, but in building robust, compliant, and efficient infrastructure. It requires a mastery of the "bo